Sanjivani Paranteral Ltd (BSE: 531569), a renowned pharmaceutical company based in Mumbai with manufacturing facilities in Navi Mumbai and Dehradun, has announced impressive financial results for the fourth quarter of FY24, showcasing significant growth and strategic expansions.

Financial Performance Highlights:

In Q4 FY24, Sanjivani Paranteral reported a substantial increase in revenue, which grew 58.38% year-over-year to Rs. 128.64 million. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw a notable rise of 59.9% to Rs. 22.10 million, with an EBITDA margin of 17.18%. Profit After Tax (PAT) grew by 26.2% to Rs. 12.58 million, achieving a PAT margin of 9.78%.

For the fiscal year FY24, the company’s revenue from operations grew by 53.31% year-over-year to Rs. 544.1 million. However, despite the growth in revenue and EBITDA, which stood at Rs. 87.58 million (up 41.47% YoY), the EBITDA margin slightly declined by 135 basis points to 16.10%, influenced by lower price realization in some products. Similarly, PAT increased by 36.65% to Rs. 61.65 million, with a slight decrease in PAT margin by 138 basis points to 11.33%.

Segment-wise and Market-wise Performance:

– Injectables: Revenue from injectables grew by 52.90% YoY to Rs. 81.1 million.

– Oral Products: Revenue from oral products increased by 66.23% YoY to Rs. 42.94 million.

– Nutraceuticals: Demonstrated the highest growth rate, with revenue soaring by 137% YoY to Rs. 4.59 million.

In terms of geographical distribution, exports, including export incentives, constituted 73% of total revenue. The core markets, including CIS countries (including Russia), the Middle East & Africa, and Latin America, contributed significantly, accounting for 66.85% of the revenue, totaling Rs. 86 million.

Company’s Outlook and Expansion Strategy:

Mr. Ashwani Khemka, Chairman & Managing Director of Sanjivani Paranteral, expressed optimism about the future, citing strategic investments in expanding into new geographies and introducing innovative products. “We are excited about the opportunities that lie ahead for Sanjivani Paranteral. Our strategic investments have positioned us for continued success and sustainable growth,” said Khemka.

Sanjivani Paranteral’s performance in FY24 reflects a robust growth trajectory and a strategic foresight in diversifying its product offerings and expanding its global footprint. The company’s focus on enhancing its product portfolio across various therapeutic areas, combined with its expansion in key international markets, positions it well for future growth amidst an evolving healthcare landscape.

  financial results FY24, Healthcare Expansion, pharmaceutical growth, Pharmaceutical Industry, Sanjivani Paranteral Ltd